Literature DB >> 23307977

Multiple myeloma, version 1.2013.

Kenneth C Anderson1, Melissa Alsina, William Bensinger, J Sybil Biermann, Adam D Cohen, Steven Devine, Benjamin Djulbegovic, Edward A Faber, Cristina Gasparetto, Francisco Hernandez-Illizaliturri, Carol Ann Huff, Adetola Kassim, Amrita Y Krishnan, Michael Liedtke, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P Treon, Donna Weber, Joachim Yahalom, Furhan Yunus, Dorothy A Shead, Rashmi Kumar.   

Abstract

These NCCN Guidelines Insights highlight the important updates/changes specific to the management of relapsed or progressive disease in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include the addition of new regimens as options for salvage therapy and strategies to mitigate the adverse effects and risks associated with newer regimens for the treatment of multiple myeloma.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23307977     DOI： 10.6004/jnccn.2013.0004

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  20 in total

Review 1.  European perspective on multiple myeloma treatment strategies in 2014.

Authors:  Heinz Ludwig; Pieter Sonneveld; Faith Davies; Joan Bladé; Mario Boccadoro; Michele Cavo; Gareth Morgan; Javier de la Rubia; Michel Delforge; Meletios Dimopoulos; Hermann Einsele; Thierry Facon; Hartmut Goldschmidt; Philippe Moreau; Hareth Nahi; Torben Plesner; Jesús San-Miguel; Roman Hajek; Pia Sondergeld; Antonio Palumbo
Journal:  Oncologist       Date:  2014-07-25

2.  Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.

Authors:  Meletios A Dimopoulos; Robert Z Orlowski; Thierry Facon; Pieter Sonneveld; Kenneth C Anderson; Meral Beksac; Lotfi Benboubker; Huw Roddie; Anna Potamianou; Catherine Couturier; Huaibao Feng; Ozlem Ataman; Helgi van de Velde; Paul G Richardson
Journal:  Haematologica       Date:  2014-09-26       Impact factor: 9.941

3.  The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma.

Authors:  Bingzong Li; Jinxiang Fu; Ping Chen; Xueping Ge; Yali Li; Isere Kuiatse; Hua Wang; Huihan Wang; Xingding Zhang; Robert Z Orlowski
Journal:  J Biol Chem       Date:  2015-10-19       Impact factor: 5.157

4.  Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.

Authors:  L Xu; Z R Hunter; G Yang; Y Cao; X Liu; R Manning; C Tripsas; J Chen; C J Patterson; M Kluk; S Kanan; J Castillo; N Lindeman; S P Treon
Journal:  Leukemia       Date:  2014-02-10       Impact factor: 11.528

5.  Novel agent induction therapy alone or followed by autologous stem cell transplantation in younger patients with multiple myeloma: A single-center retrospective study of 114 cases.

Authors:  Yan Wang; Pengpeng Xu; Yubao Chen; Qingye Fan; Junmin Li; Weili Zhao; Jianqing Mi; Hua Yan
Journal:  Mol Clin Oncol       Date:  2015-10-16

6.  Older patients with myeloma derive similar benefit from autologous transplantation.

Authors:  Manish Sharma; Mei-Jie Zhang; Xiaobo Zhong; Muneer H Abidi; Görgün Akpek; Ulrike Bacher; Natalie S Callander; Angela Dispenzieri; César O Freytes; Henry C Fung; Robert Peter Gale; Cristina Gasparetto; John Gibson; Leona A Holmberg; Tamila L Kindwall-Keller; Thomas R Klumpp; Amrita Y Krishnan; Heather J Landau; Hillard M Lazarus; Sagar Lonial; Angelo Maiolino; David I Marks; Paulette Mehta; Joseph R Mikhael Med; Taiga Nishihori; Richard Olsson; Muthalagu Ramanathan; Vivek Roy; Bipin N Savani; Harry C Schouten; Emma Scott; Jason Tay; Luen Bik To; David H Vesole; Dan T Vogl; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-18       Impact factor: 5.742

7.  Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

Authors:  Shaji K Kumar; William I Bensinger; Todd M Zimmerman; Craig B Reeder; James R Berenson; Deborah Berg; Ai-Min Hui; Neeraj Gupta; Alessandra Di Bacco; Jiang Yu; Yaping Shou; Ruben Niesvizky
Journal:  Blood       Date:  2014-06-05       Impact factor: 22.113

Review 8.  Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.

Authors:  Srinath Sundararajan; Abhijeet Kumar; Neha Korde; Amit Agarwal
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

9.  Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy.

Authors:  C Phipps; M Linenberger; L A Holmberg; D Green; P Becker; L Connelly-Smith; Z Klippel; N Burwick; A Gopal; W I Bensinger; E Libby
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

10.  Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.

Authors:  Deepti Soodgupta; Haiying Zhou; Wissam Beaino; Lan Lu; Michael Rettig; Mark Snee; James Skeath; John F DiPersio; Walter J Akers; Richard Laforest; Carolyn J Anderson; Michael H Tomasson; Monica Shokeen
Journal:  J Nucl Med       Date:  2016-01-07       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.